Genetic Tech Limited Sponsored Adr (NASDAQ:GENE) Stock Is Shorted More

February 12, 2018 - By Darrin Black

 Genetic Tech Limited Sponsored Adr (NASDAQ:GENE) Stock Is Shorted More

The stock of Genetic Tech Limited Sponsored Adr (NASDAQ:GENE) registered an increase of 10.27% in short interest. GENE’s total short interest was 557,100 shares in February as published by FINRA. Its up 10.27% from 505,200 shares, reported previously. With 200,200 shares average volume, it will take short sellers 3 days to cover their GENE’s short positions. The short interest to Genetic Tech Limited Sponsored Adr’s float is 4.1%.

It closed at $1.85 lastly. It is down 49.77% since February 12, 2017 and is downtrending. It has underperformed by 66.47% the S&P500.

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the womenÂ’s health. The company has market cap of $30.81 million. The companyÂ’s lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It currently has negative earnings. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States.

More notable recent Genetic Technologies Limited (NASDAQ:GENE) news were published by: which released: “Fast-Growing Genetic Technologies A Buyout Target? Institutional Investors …” on August 07, 2013, also with their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on January 09, 2018, published: “Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of …” on January 29, 2018. More interesting news about Genetic Technologies Limited (NASDAQ:GENE) were released by: and their article: “Genetic Technologies Ltd. ADR GENE (US: Nasdaq)” published on February 12, 2011 as well as‘s news article titled: “Genetic Technologies Ltd. ADR” with publication date: July 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.